Hengrui Pharmaceutical toluene sulphate ruimalun was approved for listing!

Toluene sulfonate is a benzodiazepine drug that acts on GABAa receptors.
March 2018, Hengrui Pharmaceuticals submitted a listing application for toluene sulfonate and accepted it, and in April of the same year, it was included in the priority review by the Drug Review Center of the State Drug Administration on the grounds that it had "a clear therapeutic advantage over existing treatment methods".
this is also the first domesticclass 1 chemical drug to be declared listed since 2018.
was developed by Paion AG for general anaesthetic during surgery.
2012, Renfu Pharma acquired the right to develop Remazolin in China from Paion AG for 3 million euros.
November 2018, Renfu Pharma submitted a listing application for benzosulfoate and accepted it (acceptance no. CXHS1800034/CXHS1800035).
April 2019, Paion AG filed a new drug application for ammarite in the U.S. FDA.
toluene sulfonate rematoludes is a salt-changing compound of Rinmaazole, which has higher stability, faster effect and advantages in safety. the
the launch of the injectable toluene sulfonate rematoriazole will provide new drug options for routine gastroscopy sedation.
.